Spots Global Cancer Trial Database for recurrent gastric carcinoma

Every month we try and update this database with for recurrent gastric carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer	NCT01178944	Adenocarcinoma ... Esophageal Undi... Gastric Adenoca... Gastric Squamou... Recurrent Esoph... Recurrent Esoph... Recurrent Gastr... Stage IIIB Esop... Stage IIIB Esop... Stage IIIB Gast... Stage IIIC Esop... Stage IIIC Esop... Stage IIIC Gast... Stage IV Esopha... Stage IV Esopha... Stage IV Gastri... Undifferentiate...	Laboratory Biom... Oxaliplatin Pralatrexate	18 Years -	Roswell Park Cancer Institute
Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients	NCT04213794	Malignant Abdom... Malignant Pelvi... Recurrent Colon... Recurrent Desmo... Recurrent Fallo... Recurrent Gastr... Recurrent Lipos... Recurrent Malig... Recurrent Ovari... Recurrent Prima... Recurrent Recta... Recurrent Rhabd... Recurrent Sarco... Refractory Colo... Refractory Desm... Refractory Fall... Refractory Gast... Refractory Lipo... Refractory Mali... Refractory Ovar... Refractory Prim... Refractory Rect... Refractory Rhab... Refractory Sarc... Resectable Lipo... Resectable Mali... Resectable Sarc...	Cisplatin Cytoreductive S... Doxorubicin Hyperthermic In... Sodium Thiosulf... Computed Tomogr... Magnetic Resona... Positron Emissi... Biospecimen Col...	1 Year - 25 Years	Mayo Clinic
Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery	NCT03008278	Metastatic Esop... Metastatic Gast... Metastatic Gast... Recurrent Esoph... Recurrent Gastr... Recurrent Gastr... Stage III Esoph... Stage III Gastr... Stage IV Esopha... Stage IV Gastri... Unresectable Es... Unresectable Ga... Unresectable Ga...	Olaparib Ramucirumab	18 Years -	National Cancer Institute (NCI)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	NCT02465060	Advanced Lympho... Advanced Malign... Bladder Carcino... Breast Carcinom... Cervical Carcin... Colon Carcinoma Colorectal Carc... Endometrial Car... Esophageal Carc... Gastric Carcino... Glioma Head and Neck C... Hematopoietic a... Kidney Carcinom... Liver Carcinoma Lung Carcinoma Lymphoma Malignant Uteri... Melanoma Multiple Myelom... Ovarian Carcino... Pancreatic Carc... Prostate Carcin... Rectal Carcinom... Recurrent Bladd... Recurrent Breas... Recurrent Cervi... Recurrent Colon... Recurrent Color... Recurrent Esoph... Recurrent Gastr... Recurrent Gliom... Recurrent Head ... Recurrent Liver... Recurrent Lung ... Recurrent Lymph... Recurrent Malig... Recurrent Melan... Recurrent Multi... Recurrent Ovari... Recurrent Pancr... Recurrent Prost... Recurrent Recta... Recurrent Skin ... Recurrent Thyro... Recurrent Uteri... Refractory Lymp... Refractory Mali... Refractory Mult... Skin Carcinoma Thyroid Gland C... Uterine Corpus ...	Adavosertib Afatinib Afatinib Dimale... Binimetinib Biopsy Biospecimen Col... Capivasertib Computed Tomogr... Copanlisib Copanlisib Hydr... Crizotinib Cytology Specim... Dabrafenib Dabrafenib Mesy... Dasatinib Defactinib Defactinib Hydr... Echocardiograph... Erdafitinib Fexagratinib Ipatasertib Laboratory Biom... Larotrectinib Larotrectinib S... Magnetic Resona... Multigated Acqu... Nivolumab Osimertinib Palbociclib Pertuzumab PI3K-beta Inhib... Radiologic Exam... Radionuclide Im... Relatlimab Sapanisertib Sunitinib Malat... Taselisib Trametinib Trastuzumab Trastuzumab Emt... Ulixertinib Vismodegib	18 Years -	National Cancer Institute (NCI)
Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients	NCT04213794	Malignant Abdom... Malignant Pelvi... Recurrent Colon... Recurrent Desmo... Recurrent Fallo... Recurrent Gastr... Recurrent Lipos... Recurrent Malig... Recurrent Ovari... Recurrent Prima... Recurrent Recta... Recurrent Rhabd... Recurrent Sarco... Refractory Colo... Refractory Desm... Refractory Fall... Refractory Gast... Refractory Lipo... Refractory Mali... Refractory Ovar... Refractory Prim... Refractory Rect... Refractory Rhab... Refractory Sarc... Resectable Lipo... Resectable Mali... Resectable Sarc...	Cisplatin Cytoreductive S... Doxorubicin Hyperthermic In... Sodium Thiosulf... Computed Tomogr... Magnetic Resona... Positron Emissi... Biospecimen Col...	1 Year - 25 Years	Mayo Clinic
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer	NCT01260701	Adenocarcinoma ... Diffuse Gastric... Gastric Intesti... Gastric Mixed A... Recurrent Gastr...	Akt Inhibitor M...	18 Years -	National Cancer Institute (NCI)
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer	NCT01260701	Adenocarcinoma ... Diffuse Gastric... Gastric Intesti... Gastric Mixed A... Recurrent Gastr...	Akt Inhibitor M...	18 Years -	National Cancer Institute (NCI)
Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer	NCT01178944	Adenocarcinoma ... Esophageal Undi... Gastric Adenoca... Gastric Squamou... Recurrent Esoph... Recurrent Esoph... Recurrent Gastr... Stage IIIB Esop... Stage IIIB Esop... Stage IIIB Gast... Stage IIIC Esop... Stage IIIC Esop... Stage IIIC Gast... Stage IV Esopha... Stage IV Esopha... Stage IV Gastri... Undifferentiate...	Laboratory Biom... Oxaliplatin Pralatrexate	18 Years -	Roswell Park Cancer Institute

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: